BI 1323495 + itraconazole

**BI 1323495 + itraconazole** refers to the concomitant use of the investigational drug BI 1323495 and the antifungal agent itraconazole in clinical research. **BI 1323495** is an oral, reversible small molecule inhibitor of neutrophil elastase (NE, also known as ELA2), developed for chronic lung diseases characterized by neutrophilic airway inflammation such as non-cystic fibrosis bronchiectasis. Itraconazole, an oral CYP3A4 inhibitor, is used in these studies to assess potential drug-drug interactions by influencing the metabolism of BI 1323495, particularly in human subjects with specific UGT2B17 genotypes. There is no evidence that this combination is a unique commercial product; it is used as part of a pharmacokinetic interaction study[7]. BI 1323495 acts by inhibiting neutrophil elastase, a protease implicated in airway tissue damage, inflammation, and mucus hypersecretion in certain lung diseases[2][4].